Free Trial

SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$0.71 +0.01 (+1.58%)
As of 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SCYX vs. BHST, GNLX, TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, and MCRB

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include BioHarvest Sciences (BHST), Genelux (GNLX), Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

SCYNEXIS vs. Its Competitors

BioHarvest Sciences (NASDAQ:BHST) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

BioHarvest Sciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

BioHarvest Sciences currently has a consensus price target of $13.67, indicating a potential upside of 89.03%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe BioHarvest Sciences is more favorable than SCYNEXIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
SCYNEXIS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

54.4% of SCYNEXIS shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioHarvest Sciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for SCYNEXIS. BioHarvest Sciences' average media sentiment score of 0.78 beat SCYNEXIS's score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company Overall Sentiment
BioHarvest Sciences Positive
SCYNEXIS Neutral

BioHarvest Sciences has higher revenue and earnings than SCYNEXIS. BioHarvest Sciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$25.19M4.71-$12.91M-$0.50-14.46
SCYNEXIS$3.75M7.35-$21.29M-$0.56-1.26

BioHarvest Sciences has a net margin of -31.30% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-31.30% -307.04% -33.21%
SCYNEXIS -1,030.04%-53.47%-32.86%

Summary

BioHarvest Sciences beats SCYNEXIS on 9 of the 16 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.55M$2.43B$5.58B$9.01B
Dividend YieldN/A1.80%5.25%4.03%
P/E Ratio-1.269.3627.5120.20
Price / Sales7.35607.63415.84172.51
Price / CashN/A161.3437.0657.97
Price / Book0.494.668.085.61
Net Income-$21.29M$31.26M$3.17B$248.50M
7 Day Performance-3.42%6.62%3.57%4.92%
1 Month Performance-19.95%3.85%3.74%7.42%
1 Year Performance-64.16%3.16%33.78%21.48%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
0.2751 of 5 stars
$0.71
+1.6%
N/A-64.5%$27.55M$3.75M-1.2660
BHST
BioHarvest Sciences
N/A$7.06
+2.3%
$13.67
+93.6%
N/A$113.33M$27.70M-14.12N/ANews Coverage
High Trading Volume
GNLX
Genelux
1.9848 of 5 stars
$2.90
-2.7%
$17.75
+512.1%
+59.4%$112.45MN/A-3.3010
TARA
Protara Therapeutics
1.4503 of 5 stars
$2.80
-3.1%
$20.50
+632.1%
+51.2%$111.50MN/A-1.6330
ATOS
Atossa Genetics
1.5812 of 5 stars
$0.85
-0.4%
$6.17
+629.1%
-21.7%$109.68MN/A-4.038
HURA
TuHURA Biosciences
1.2307 of 5 stars
$2.40
-3.2%
$12.67
+427.8%
N/A$108.33MN/A0.00N/A
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.2%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
CCCC
C4 Therapeutics
1.4463 of 5 stars
$1.52
+2.7%
$12.00
+689.5%
-59.6%$105.09M$35.58M-1.03150
ANIX
Anixa Biosciences
3.1471 of 5 stars
$3.21
-0.6%
$9.00
+180.4%
+42.5%$104.04M$210K-8.455News Coverage
MIST
Milestone Pharmaceuticals
3.2013 of 5 stars
$2.17
+11.9%
$7.00
+222.6%
+65.5%$103.72M$1M-2.7830High Trading Volume
MCRB
Seres Therapeutics
3.5709 of 5 stars
$10.85
-8.6%
$73.67
+579.0%
-39.3%$103.65M$126.32M-2.36330Positive News

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners